Program
TDI01
A development code. Also written as “TDI01 suspension”.
In Sino Biopharmaceutical's pipeline, ROCK2抑制剂
. Its studies are mostly in Idiopathic Pulmonary Fibrosis · Bronchiolitis Obliterans Syndrome, led by Sino Biopharmaceutical.
Furthest: phase 3, since Dec 24, 20253 company-led studies, 3 open or runningNext primary completion: Jul 30, 2029 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 33 open or running | phase 3since Dec 24, 2025 | Jul 31, 2023 | Jul 30, 2029phase 3 · NCT07464912 |
- Named in Sino Biopharmaceutical’s own pipeline as
TDI01
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 31, 2023First study: phase 2 study in Idiopathic Pulmonary FibrosisFirst studyNCT06102083 · 120 planned
- Dec 5, 2023Phase 2 study in Bronchiolitis Obliterans SyndromeNCT06169722 · 60 enrolled · China
- Dec 24, 2025Phase 3 study in Idiopathic Pulmonary FibrosisPhase 3 reachedNCT07464912 · 508 planned · China
Ahead
- Jul 30, 2029Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT07464912
TargetBeta
“ROCK2抑制剂”the company's pipeline, read by Claude · source
Other programs on ROCK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| belumosudilrule | Sanofi | phase 4 | 26 |
| netarsudilrule | Alcon | phase 4 | 20 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07464912Idiopathic Pulmonary Fibrosis · China | 3 | Recruiting | Jul 30, 2029 | 508 |
| NCT06169722Bronchiolitis Obliterans Syndrome · China | 2 | Active, not recruiting | Feb 2026 | 60 |
| NCT06102083Idiopathic Pulmonary Fibrosis | 2 | Not yet recruiting | Aug 1, 2025 | 120 |
How it is read
Names in the registry
- “TDI01 suspension”, 2 entries
- “TDI01”, 1 entry
Codes read as this program: TDI01.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 2 studies
- Bronchiolitis Obliterans Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.